Treatment of skin, and wound repair, with thymosin beta 4

1 . A cosmetic composition for topical treatment of skin, comprising from 0. 1 ng/ml to 10 μg/ml of human thymosin β4; and a cosmetically acceptable vehicle.

2 . The cosmetic composition according to claim 1 , further comprising human transforming growth factor β1 at a concentration from 5 pg to 1 ≢g/ml.

3 . The cosmetic composition according to claim 2 , further comprising human vascular endothelial growth factor at a concentration from 1 pg/ml to 1 βg/ml.

4 . The composition according to claim 3 , and further comprising one or more of estradiol; progesterone; pregnanalone; coenzyme Q10; methylsolanomethane (MSM); copper peptide (copper extract); plankton extract (phytosome); tumor growth factor beta 1 (TGF-β1); glycolic acid; kojic acid; ascorbyl palmitate; all trans retinol; azaleic acid; salicylic acid; broparoestrol; estrone; adrostenedione; and androstanediol.

5 . The composition according to claim 3 , wherein said composition further comprises a sunblock.

6 . The composition according to claim 3 , wherein said cosmetically acceptable vehicle is an oil in water, or water in oil emulsion.

7 . A method for improving the appearance of the skin, the method comprising:

applying topically a cosmetic composition comprising from 0.1 ng/ml to 10 μg/ml of human thymosin β4; and a cosmetically acceptable vehicle.

8 . The method according to claim 7 , further comprising human transforming growth factor β1 at a concentration from 5 pg to 1 μ/ml.

9 . The method according to claim 7 , further comprising human vascular endothelial growth factor at a concentration from 1 pg/ml to 1 μ/ml.

10 . The method according to claim 9 , wherein said skin is aged, photoaged, dry, lined or wrinkled skin.

11 . The method according to claim 10 , wherein said composition further comprises one or more of estradiol; progesterone; pregnanalone; coenzyme Q10; methylsolanomethane (MSM); copper peptide (copper extract); plankton extract (phytosome); tumor growth factor beta 1 (TGF-β1); glycolic acid; kojic acid; ascorbyl palmitate; all trans retinol; azaleic acid; salicylic acid; broparoestrol; estrone; adrostenedione; and androstanediols.

12 . The method according to claim 10 , wherein said composition further comprises a sunblock.

13 . The method according to claim 10 , wherein said cosmetically acceptable vehicle is an oil in water, or water in oil emulsion.

14 . A cosmetic composition for topical treatment of skin, comprising from 0.1 ng/ml to 1 μ/ml of human thymosin β4; and a cosmetically acceptable vehicle.

15 . A cosmetic composition for topical treatment of skin, comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4; human transforming growth factor β1 at a concentration from 5 pg to 1 μg/ml, and a cosmetically acceptable vehicle.

16 . A cosmetic composition for topical treatment of skin, comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4; human vascular endothelial growth factor at a concentration from 1 pg/ml to 1 μg/ml and a cosmetically acceptable vehicle.

17 . The composition according to claim 16 , and further comprising one or more of estradiol, progesterone; pregnanalone; coenzyme Q10; methylsolanomethane (MSM); copper peptide (copper extract); plankton extract (phytosome); glycolic acid; kojic acid; ascorbyl palmitate; all trans retinol; azaleic acid; salicylic acid; broparoestrol; estrone; adrostenedione; and androstanediol.

18 . The composition according to claim 16 , wherein said composition further comprises a sunblock.

19 . The composition according to claim 16 , wherein said cosmetically acceptable vehicle is an oil in water, or water in oil emulsion.

20 . A method for improving the appearance of the skin, the method comprising:

applying topically a cosmetic composition comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4; and a cosmetically acceptable vehicle.

21 . A method for improving the appearance of the skin, the method comprising:

applying topically a cosmetic composition comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4, human transforming growth factor β1 at a concentration from 5 pg to 1 μg/ml, and a cosmetically acceptable vehicle.

22 . A method for improving the appearance of the skin, the method comprising:

applying topically a cosmetic composition comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4, human vascular endothelial growth factor at a concentration from 1 pg/ml to 1 μg/ml, and a cosmetically acceptable vehicle.

23 . The method according to claim 22 , wherein said skin is aged, photoaged, dry, lined or wrinkled skin.

24 . The method according to claim 23 , wherein said composition further comprises one or more of estradiol; progesterone; pregnanalone; coenzyme Q10; methylsolanomethane (MSM); copper peptide (copper extract); plankton extract (phytbsome); glycolic acid; kojic acid; ascorbyl palmitate; all trans retinol; azaleic acid; salicylic acid; broparoestrol; estrone; adrostenedione; and androstanediols.

25 . The method according to claim 23 , wherein said composition further comprises a sunblock.

26 . The method according to claim 23 , wherein said cosmetically acceptable vehicle is an oil in water, or water in oil emulsion.

27 . A method for preventing or treating damaged skin, the method comprising:

applying topically a composition comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4; and a vehicle.

28 . The method according to claim 27 , wherein the concentration of human thymosin β4 is from at least about 0.1 ng/ml to 1 μg/ml.

29 . A method for preventing or treating damaged skin, the method comprising:

applying topically a composition comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4, human transforming growth factor β1, and vehicle.

30 . The method according to claim 29 , wherein the concentration of human thymosin β4 is from at least about 0.1 ng/ml to 1μg/ml.

31 . A method for preventing or treating damaged skin, the method comprising:

applying topically a composition comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4, human vascular endothelial growth factor, and a vehicle.

32 . The method according to claim 31 , wherein the concentration of human thymosin β4 is from at least about 0.1 ng/ml to 1 μg/ml.

33 . A composition, comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4 and a vehicle.

34 . The method according to claim 33 , wherein the concentration of human thymosin β4 is from at least about 0.1 ng/ml to 1 μg/ml.

35 . The composition of claim 33 , further comprising human transforming growth factor β1.

36 . The composition of claim 33 , further comprising human vascular endothelial growth factor.

37 . The composition according to claim 33 , wherein the vehicle is an emulsion.

38 . A method for treating epithelial tissue, the method comprising:

administering to a subject a composition comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4 and a vehicle.

39 . The method of according to claim 38 , wherein the tissue is skin.

40 . The method of claim 38 , wherein said composition further comprises human transforming growth factor β1.

41 . The method of claim 38 , wherein said composition further comprises human vascular endothelial growth factor.

42 . The method according to claim 39 , wherein the skin is aged, photoaged, dry, lined or wrinkled skin.

43 . The method of claim 38 , wherein the vehicle is an emulsion.

44 . A method for improving appearance of skin, the method comprising:

administering to a subject a composition comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4; and a vehicle.

45 . The method according to claim 44 , wherein the concentration of human thymosin β4 is from at least about 0.1 ng/ml to 1 μg/ml.

46 . The method of claim 44 , wherein said composition further comprises human transforming growth factor β1.

47 . The method of claim 44 , wherein said composition further comprises human vascular endothelial growth factor.